Emergent BioSolutions Inc. (EBS)
Market Cap | 658.03M |
Revenue (ttm) | 1.51B |
Net Income (ttm) | 53.50M |
Shares Out | 49.89M |
EPS (ttm) | 0.78 |
PE Ratio | 16.91 |
Forward PE | 7.94 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 808,051 |
Open | 13.00 |
Previous Close | 12.92 |
Day's Range | 13.00 - 13.40 |
52-Week Range | 10.61 - 47.71 |
Beta | 0.89 |
Analysts | Buy |
Price Target | 31.11 (+135.86%) |
Earnings Date | Feb 23, 2023 |
About EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat b... [Read more]
Full Company ProfileFinancial Performance
In 2021, EBS's revenue was $1.79 billion, an increase of 15.26% compared to the previous year's $1.56 billion. Earnings were $230.90 million, a decrease of -24.32%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $31.11, which is an increase of 135.86% from the latest price.
News

Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.

Emergent BioSolutions to cut 5% of its workforce in reorganization effort
Emergent BioSolutions Inc. EBS, +9.80% is cutting 132 jobs, or approximately 5% of its workforce in a reorganization that the company says will sharpen its strategic focus on core businesses. The biot...

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a ma...

Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
GAITHERSBURG, Md., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Ne...

4 Toxic Stocks More So Hazardous Amid Volatile Times
Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a fe...

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies Emergent partners with the Armed Forces Research...

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

Emergent BioSolutions Reports Financial Results For Third Quarter 2022
GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022.

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company's adjuvanted s...

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst
These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial r...

Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofo...

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immu...

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

3 Top Monkeypox Stocks to Buy Right Now
With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat...

Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following in...

Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.

Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent BioSolutions Reports Financial Results for Second Quarter 2022
GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.